No Data
No Data
The actual controller of Chinese Health (301408.SZ) pledges 28 million shares
Chinese Health (301408.SZ) announced that He Jiale, the controlling shareholder and actual controller of the company, held 280...
The pharmaceutical business sector fluctuated and picked up. Yu Shu Min rose 20 cm, Dajia Weikang rose more than 15%, and Pharma Tesco, Chinese Health, Inter Group, Hefu China, and Guoke Hengtai followed suit.
The pharmaceutical business sector fluctuated and picked up. Yu Shu Min rose 20 cm, Dajia Weikang rose more than 15%, and Pharma Tesco, Chinese Health, Inter Group, Hefu China, and Guoke Hengtai followed suit.
Anhui Huaren Health Pharmaceutical: Anhui Chinese Health Pharmaceutical Co., Ltd. 2023 Annual Report (updated)
Express News | Chinese Health: Through measures such as improving logistics efficiency, the company's gross margin will be effectively increased
The pharmaceutical sector boosted and strengthened. Zhejiang Zhenyuan rose more than 5%, while Chinese Health, Heavy Pharmaceutical Holdings, Intel Group, Nanjing Pharmaceuticals, Sinopharm, and Kyushu Express followed suit.
The pharmaceutical sector boosted and strengthened. Zhejiang Zhenyuan rose more than 5%, while Chinese Health, Heavy Pharmaceutical Holdings, Intel Group, Nanjing Pharmaceuticals, Sinopharm, and Kyushu Express followed suit.
Chinese Health (301408.SZ) announced its 2023 annual results, with net profit of 115 million yuan, a decrease of 28.68%
Chinese Health (301408.SZ) released its 2023 annual report. During the reporting period, the company achieved operating income of 3...
No Data